Compare FNGR & BNGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FNGR | BNGO |
|---|---|---|
| Founded | 2016 | 2003 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0M | 12.5M |
| IPO Year | 2014 | 2018 |
| Metric | FNGR | BNGO |
|---|---|---|
| Price | $0.15 | $1.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 54.9M | 156.3K |
| Earning Date | 05-28-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.50 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,132,261.00 | $12,000,735.00 |
| Revenue This Year | N/A | $14.99 |
| Revenue Next Year | N/A | $34.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 26.26 |
| 52 Week Low | $0.15 | $1.00 |
| 52 Week High | $2.20 | $2.16 |
| Indicator | FNGR | BNGO |
|---|---|---|
| Relative Strength Index (RSI) | 39.72 | 88.46 |
| Support Level | N/A | $1.09 |
| Resistance Level | $0.37 | N/A |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 0.19 | 86.10 |
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The Company organizes its operations across four primary areas: telecommunications products and services, marketplace platform and digital commerce infrastructure solutions, data and analytics platform solutions, and Advanced Technology And Platform Solutions. The company generates majority of revenue from telecommunications products and services segment. This segment includes mobile payment and recharge services, as well as enterprise messaging services such as short message services (SMS) and multimedia messaging services (MMS).
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.